Ignite Creation Date:
2024-05-05 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00521287
Status:
UNKNOWN
Last Update Posted:
2008-03-03
First Post:
2007-08-24
Brief Title:
Impaired Immunity in Patients With Cancer Influence of Cancer Stage Chemotherapy and Cytomegalovirus Infection
Sponsor:
Mackay Memorial Hospital
Organization:
Mackay Memorial Hospital
Study Overview
Official Title:
Adjustment of Optimal Immune System by Using Cytokine Cocktails Before Applying DC Vaccine
Status:
UNKNOWN
Status Verified Date:
2007-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
According to a survey from Department of Health in 2004 cancer has been the leading cause of death in the Taiwan area In 2004 people died of cancer accounting for 272 percent of all deaths The major reason of the superior grade is that cancer has the ability to escape the surveillance of immune system It is also a main issue to address in medical research
Dendritic cells DCs the most potent APC are located at sites of pathogen entry acquire antigens from pathogens or pathogen-infected cells and process these antigens for both class I and class II presentation Upon antigen encounter they termed immature DCs undergo a maturation process they are capable to present captured antigens to T cells This maturation step allows DC migration to trigger adaptive immune responses These features make DCs very good candidates for therapy against various pathological conditions including malignancies
Therefore two concepts in this project will be concerned one is enhancement of T cell immunity and the other is improvement of the efficiency of DC-tumor fusion The strategy of enhance T cell is using well-known cytokines such as IL2 and IL7 to expand the tumor-specific CD4 and CD8 T cells before DC-vaccine treatment In the past scientists utilized polyethyleneglycol to fuse cancer cells and dendritic cells However the results were devastating Two new approaches of the DC vaccine will be applied to this study DC-tumor fusion and DC phagocytosed apoptosed tumor cells Whole tumor cells will be fused with DCs by combining hypotonic buffer and electrical-based fusion protocols The safety of hybrid cell vaccination has been shown in clinical trials with some encouraging anti-tumour effects However data are as yet insufficient to assess a clear therapeutic benefit Hopefully the combination of two strategies will improve the efficiency of DC vaccine and boost survival of cancer patients
As we have gained a clearer understanding of the cellular and molecular events that modulate antigen presentation and T cell activation in vivo new strategies have emerged allowing the development of more potent second generation DC vaccines
Dendritic cells DCs the most potent APC are located at sites of pathogen entry acquire antigens from pathogens or pathogen-infected cells and process these antigens for both class I and class II presentation Upon antigen encounter they termed immature DCs undergo a maturation process they are capable to present captured antigens to T cells This maturation step allows DC migration to trigger adaptive immune responses These features make DCs very good candidates for therapy against various pathological conditions including malignancies
Therefore two concepts in this project will be concerned one is enhancement of T cell immunity and the other is improvement of the efficiency of DC-tumor fusion The strategy of enhance T cell is using well-known cytokines such as IL2 and IL7 to expand the tumor-specific CD4 and CD8 T cells before DC-vaccine treatment In the past scientists utilized polyethyleneglycol to fuse cancer cells and dendritic cells However the results were devastating Two new approaches of the DC vaccine will be applied to this study DC-tumor fusion and DC phagocytosed apoptosed tumor cells Whole tumor cells will be fused with DCs by combining hypotonic buffer and electrical-based fusion protocols The safety of hybrid cell vaccination has been shown in clinical trials with some encouraging anti-tumour effects However data are as yet insufficient to assess a clear therapeutic benefit Hopefully the combination of two strategies will improve the efficiency of DC vaccine and boost survival of cancer patients
As we have gained a clearer understanding of the cellular and molecular events that modulate antigen presentation and T cell activation in vivo new strategies have emerged allowing the development of more potent second generation DC vaccines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MMH-I-S-401 | None | None | None |